Conformation-Stabilizing Integrin α7β1 Antibodies for Sarcolemma Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies, such as Duchenne Muscular Dystrophy (DMD), primarily focus on mitigating symptoms and improving quality of life, lacking effective approaches to address the underlying muscle membrane integrity issues.
Innovation Solution
Development of integrin α7β1 antibodies that stabilize the α7β1 integrin in extended-closed and extended-open conformations, enhancing muscle membrane adhesion to the extracellular matrix, thereby restoring damaged sarcolemma and reducing fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If existing treatments (glucocorticoids, physical therapy, orthopedic devices) are used to mitigate symptoms of muscular dystrophy, then quality of life is improved, but the underlying muscle membrane integrity issues are not addressed
Solution Approach 1:
The patent uses antibodies (20TFT and TS2/16) as intermediary molecules that bind to integrin α7β1 to restore muscle membrane integrity. These antibodies act as mediators between the defective dystrophin-glycoprotein complex and the integrin, compensating for the underlying structural defect without replacing the entire complex.
Solution Approach 2:
The patent changes the conformational parameters of integrin α7β1 by stabilizing it in extended-open or extended-closed states. This parameter change (from bent-closed to extended conformations) restores the integrin's ability to bind laminin and maintain muscle membrane integrity, addressing the root cause rather than just symptoms.
2Strength
If integrin α7β1 is stabilized in extended conformations to enhance laminin binding, then muscle membrane adhesion is improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent employs antibodies with multiple functions: they bind to integrin α7β1, stabilize specific conformations, enhance laminin binding affinity, and compensate for dystrophin deficiency. This multi-functionality reduces the need for separate therapeutic agents for each function, simplifying the overall therapeutic approach despite the molecular complexity.
3Manufacturing precision
If antibodies are designed to bind to specific epitopes of integrin α7β1 to stabilize extended conformations, then binding affinity to laminin is enhanced, but the difficulty of detecting and measuring the correct epitope increases
Solution Approach 1:
The patent uses functional assays that measure laminin binding affinity and muscle membrane stabilization as feedback to identify and validate the correct epitopes. The 20TFT and TS2/16 antibodies were developed and optimized based on their ability to stabilize integrin in extended conformations and enhance laminin binding, with their epitopes identified through competitive binding assays and conformational analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies increase muscle adhesion, improve locomotive ability, and enhance muscle force in patients with dystrophinopathies by stabilizing α7β1 integrin conformations, addressing the underlying integrity issues.
Implementation Method 1
the present disclosure is based, in part, on identification of integrin α7β1 antibodies that are effective in stabilizing the α7β1 integrin in the extended-closed and extended-open conformations and therefore enhancing the binding to laminin ligands
Implementation Method 2
the anti-α7β1 antibodies of the present disclosure potently increase adhesion of muscle membranes (sarcolemma) to the extracellular matrix
Data Source
AI summary
The present disclosure provides, among other things, a class of antibodies or an antigen-binding fragments that bind to calf-1 or calf-2 domain of α7β1 integrin. The anti-α7β1 antibodies of the present disclosure are effective in stabilizing the α7β1 integrin in the extended-closed and extended-open conformations, which enhances the binding to laminins.